Pain Management — Therapeutic Area Intelligence | Humanexa Signals

ClinicalAugust 5, 2026

Pilot Trial for Simulation-Free Celiac Plexus Pain Ablation Using SBRT Shows Novel Workflow

A pilot feasibility trial is assessing a novel simulation-free adaptive radiotherapy workflow for celiac plexus SBRT.

StrategyAugust 4, 2026

Medline Issues Correction for Convenience Kits Containing Recalled Lidocaine and Bupivacaine

Medline is removing recalled Lidocaine Hydrochloride and Bupivacaine Hydrochloride from convenience kits.

ClinicalAugust 4, 2026

Evaluating Perineural Catheter for Postoperative Pain in Hindfoot Surgery

A study is assessing the efficacy of perineural catheters versus single nerve blocks for postoperative pain management in hindfoot surgery.

RegulatoryAugust 2, 2026

FDA Approves Pregabalin Application ANDA219593 by Unichem

The FDA has approved the ANDA219593 application for Pregabalin submitted by Unichem.

RegulatoryAugust 1, 2026

FDA Grants Approval for Hydromorphone Hydrochloride ANDA076444

The FDA has granted approval for ANDA076444, a supplemental application for Hydromorphone Hydrochloride by Barr.

ClinicalJuly 30, 2026

Study on Chronic Pain Patient Preferences for Medication Side Effects

A study is assessing chronic pain patients' preferences for medication side effects versus pain relief benefits.

ClinicalJuly 30, 2026

Liposomal Bupivacaine May Enhance Analgesia in Hip Fracture Surgery

A clinical trial is investigating the efficacy of liposomal bupivacaine for pain management in older patients post-hip fracture surgery.

ClinicalJuly 29, 2026

Study Compares Systemic Lidocaine to Adductor Canal Block in Knee Surgery

This study evaluates postoperative outcomes in total knee arthroplasty patients receiving systemic lidocaine versus an adductor canal block.

ClinicalJuly 28, 2026

Study on Ropivacaine Plus Triamcinolone for Postoperative Pain Relief After VATS

A multicenter, randomized controlled trial is investigating the efficacy of preemptive incisional infiltration with ropivacaine plus triamcinolone versus ropivacaine alone for postoperative pain relief after thoracoscopic surgery.

RegulatoryJuly 26, 2026

FDA Approves Supplemental Application for Milnacipran Hydrochloride

The FDA has approved a supplemental application for Milnacipran Hydrochloride submitted by Breckenridge.

StrategyJuly 26, 2026

FDA Grants AP Status for Milnacipran Hydrochloride by Amneal Pharmaceuticals

The FDA has granted Abbreviated Approval (AP) status for Milnacipran Hydrochloride submitted by Amneal Pharmaceuticals.

ClinicalJuly 26, 2026

Study on Hydromorphone in Multimodal Analgesia for Knee Arthroplasty

The study evaluates the efficacy of hydromorphone combined with ropivacaine for pain management in knee arthroplasty.

StrategyJuly 25, 2026

FDA Approves First Nonprescription Acetaminophen and Naproxen Combination for Pain Relief

The FDA has approved Tylenol with Naproxen, a fixed-dose combination for 12-hour pain relief.

StrategyJuly 25, 2026

FDA Accepts Pregabalin ANDA211687 Submission from Alvogen

The FDA has accepted Alvogen's Abbreviated New Drug Application for Pregabalin, indicating a step towards potential market entry.

StrategyJuly 24, 2026

FDA Grants Approval for Methadone Hydrochloride ANDA212093 by Lannett Co Inc

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) for Methadone Hydrochloride submitted by Lannett Co Inc.

RegulatoryJuly 24, 2026

FDA Accepts Supplement Application for Celecoxib by Alembic

The FDA has accepted a supplemental application for Celecoxib (ANDA204519) submitted by Alembic.

RegulatoryJuly 24, 2026

FDA Accepts Supplement Application for Ibuprofen and Famotidine by Alkem Labs

The FDA has accepted a supplemental application for a combination product of ibuprofen and famotidine submitted by Alkem Labs.

RegulatoryJuly 24, 2026

Aurobindo Pharma's Diclofenac Sodium ANDA076152 Receives AP Status

Aurobindo Pharma USA has received an Abbreviated New Drug Application (ANDA) approval status for Diclofenac Sodium.

RegulatoryJuly 23, 2026

FDA Grants Approval for Aurobindo's Etodolac ANDA214872

The FDA has granted approval for Aurobindo Pharma's ANDA214872 for Etodolac.

RegulatoryJuly 23, 2026

FDA Accepts Pregabalin Supplement Application ANDA209357 from MSN

The FDA has accepted a supplemental application for Pregabalin (ANDA209357) from sponsor MSN.

RegulatoryJuly 23, 2026

FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research

The FDA has approved a supplemental application for Buprenorphine Hydrochloride submitted by Rubicon Research.

RegulatoryJuly 23, 2026

FDA Grants Approval for Novitium's Tramadol Hydrochloride

The FDA has granted approval for Novitium Pharma's ANDA219647 for Tramadol Hydrochloride.

ClinicalJuly 22, 2026

Trial Comparing Liposomal Bupivacaine and Dexamethasone for Postoperative Pain Control

A trial is set to compare liposomal bupivacaine plus plain bupivacaine against dexamethasone plus plain bupivacaine in patients at risk for severe postoperative pain.

RegulatoryJuly 21, 2026

FDA Approval Letter for Morphine Sulfate by Fresenius Kabi USA

The FDA has issued an approval letter for the supplemental application of Morphine Sulfate (NDA204223) submitted by Fresenius Kabi USA.

ClinicalJuly 20, 2026

Study on Retrolaminar Block's Impact on Opioid Use in Spine Surgery

A randomized controlled trial is evaluating the effectiveness of retrolaminar block in reducing opioid consumption post-lumbar spine fusion.

ClinicalJuly 19, 2026

Trial Evaluates Superficial Cervical Block to Reduce Opioid Use in Cervical Discectomy

A randomized controlled trial is assessing the impact of superficial cervical block on opioid consumption post-anterior cervical discectomy.

ClinicalJuly 19, 2026

Study on Chronic Post-Surgical Pain Following Video-Assisted Thoracic Surgery Launched

The EVATHO study aims to assess the prevalence of chronic post-surgical pain after video-assisted thoracic surgery and identify risk factors.

ClinicalJuly 17, 2026

Study on taVNS for Postoperative Pain Management in Thoracoscopic Surgery

The study evaluates the efficacy and safety of transcutaneous auricular vagus nerve stimulation for managing postoperative pain.

RegulatoryJuly 16, 2026

FDA Approval Status Update for Buprenorphine Hydrochloride by Rubicon Research

The FDA has an active application (ANDA090279) for Buprenorphine Hydrochloride submitted by Rubicon Research.

ClinicalJuly 15, 2026

Study on Axillary Block and Analgesic Truncal Blocks for Wrist Surgery

The study investigates the efficacy of combining axillary block with analgesic blocks at the elbow for improved postoperative outcomes in wrist surgery.

CompetitiveJuly 15, 2026

BTL-043 and BTL-899 Devices Show Promise in Alleviating Back Pain

A clinical trial is underway to evaluate the safety and efficacy of BTL-043 and BTL-899 devices for back pain relief.

ClinicalJuly 15, 2026

Study Compares R.E.C.K vs Exparel for Pain Management in Robotic Nephrectomy

A study is underway to compare the efficacy of R.E.C.K and Exparel in managing postoperative pain in robotic nephrectomy.

ClinicalJuly 14, 2026

Trial on Thread-Embedding Acupuncture for Chronic Low Back Pain Initiated

A clinical trial is underway to assess the efficacy of thread-embedding acupuncture versus sham treatment in chronic low back pain.

ClinicalJuly 13, 2026

Trial on Bowen Therapy and McGill Exercises for Chronic Low Back Pain Initiated

A randomized controlled trial is comparing Bowen Therapy with McGill stabilization exercises against Bowen Therapy alone in chronic low back pain patients.

ClinicalJuly 13, 2026

Study on Shockwave Therapy for Non-Specific Low Back Pain Underway

A randomized control trial is investigating the efficacy of focused shockwave therapy on non-specific low back pain compared to conventional physiotherapy.

ClinicalJuly 12, 2026

Study on Erector Spinae Plane Block for Pain Control in Spinal Surgery

A clinical trial is evaluating the efficacy of ultrasound-guided erector spinae plane block in major spinal surgery.

ClinicalJuly 12, 2026

Study on Quadro-Iliac Plane Block for Pain Control Post-Lumbar Microdiscectomy

This study compares ultrasound-guided quadro-iliac plane block with local infiltration analgesia for postoperative pain control.

StrategyJuly 12, 2026

FDA Grants Approval for Dimethyl Sulfoxide ANDA220173

The FDA has granted approval for ANDA220173, a generic application for Dimethyl Sulfoxide submitted by STIRA.

StrategyJuly 12, 2026

FDA Grants Approval for Morphine Sulfate ANDA213892 by Quagen

The FDA has granted approval for ANDA213892, a generic version of Morphine Sulfate submitted by Quagen.

RegulatoryJuly 12, 2026

FDA Approval for Children's Advil-Flavored Supplement by Haleon

The FDA has approved the NDA for Children's Advil-Flavored Supplement, containing ibuprofen.

ClinicalJuly 12, 2026

Study on Methocarbamol for Pain Management in Hernia Repair

A clinical trial is underway to evaluate methocarbamol as a pain management option for hernia repair compared to standard opioid treatments.

StrategyJuly 11, 2026

FDA Approves Pregabalin ANDA219593 by Unichem

The FDA has approved the Abbreviated New Drug Application (ANDA) for Pregabalin submitted by Unichem.

ClinicalJuly 11, 2026

Study on Vibratory Anesthesia for Pain Management in Corticosteroid Injections

A study is evaluating the effectiveness of vibratory and vapo-coolant anesthesia compared to no anesthesia during corticosteroid injections.

ClinicalJuly 11, 2026

Study on Pain Neuroscience Education for Chronic Pain Shows Need for Biomechanical Assessment

The study aims to investigate the effectiveness of combining Pain Neuroscience Education (PNE) with Therapeutic Exercise (TE) on both pain and biomechanical parameters in chronic pain patients.

ClinicalJuly 10, 2026

Study Compares RFA Techniques for Chronic Coccydynia Pain Relief

A clinical trial is underway to compare single- and double-level radiofrequency ablation techniques for chronic coccydynia.

ClinicalJuly 9, 2026

Trial on Ultrasound-Guided Cervical Plexus Block for VNS Surgery Analgesia

A clinical trial is evaluating the efficacy of ultrasound-guided intermediate cervical plexus block for pain management in vagus nerve stimulation surgery.

ClinicalJuly 9, 2026

Acupuncture Trial for Heel Pain Syndrome Shows Promise in Pain Relief and Function

A randomized controlled trial is evaluating the efficacy of acupuncture at the Heel Pain Point for treating heel pain syndrome, comparing it to manual therapy and sham acupuncture.

RegulatoryJuly 9, 2026

FDA Grants AP Status for Hetero Labs' Naproxen ANDA215776

The FDA has granted abbreviated approval (AP) status for Hetero Labs' ANDA for Naproxen.

StrategyJuly 8, 2026

Novitium Pharma's Tramadol Hydrochloride ANDA219647 Receives AP Status

Novitium Pharma's ANDA for Tramadol Hydrochloride has received an Approval Pending (AP) status from the FDA.

RegulatoryJuly 8, 2026

FDA Accepts Supplement for Naproxen by Novitium Pharma

The FDA has accepted a supplemental application for Naproxen from Novitium Pharma.

RegulatoryJuly 8, 2026

FDA Grants Approval for Naproxen Sodium ANDA212199 by Sciegen Pharmaceuticals

The FDA has granted approval for ANDA212199, a supplemental application for Naproxen Sodium submitted by Sciegen Pharmaceuticals.

ClinicalJuly 6, 2026

Study on Dexmedetomidine vs Magnesium Sulphate for Thoracotomy Pain Management

The study compares the efficacy of dexmedetomidine and magnesium sulphate as adjuvants in erector spinae block for thoracotomy pain.

ClinicalJuly 6, 2026

Intranasal and IV Oxytocin Study for Pain Relief Shows Potential

A clinical trial is investigating the efficacy of oxytocin administered intranasally and intravenously for pain reduction.

RegulatoryJuly 3, 2026

Amneal Pharmaceuticals submits ANDA for Milnacipran Hydrochloride

Amneal Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) for Milnacipran Hydrochloride.

RegulatoryJuly 1, 2026

FDA Approval for Children's Advil-Flavored Supplement by Haleon

The FDA has approved the supplemental application for Children's Advil-Flavored, containing ibuprofen.

RegulatoryJuly 1, 2026

Strides Pharma's Piroxicam ANDA206136 Receives AP Status from FDA

Strides Pharma's ANDA for Piroxicam has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 1, 2026

FDA Grants AP Status for Piroxicam ANDA210347 by Strides Pharma

Strides Pharma has received an Abbreviated New Drug Application (ANDA) approval for Piroxicam.

ClinicalJune 30, 2026

Study on Botulinum Toxin-A for Temporomandibular Myofascial Pain Outcomes

This study aims to evaluate the effectiveness of botulinum toxin-A compared to normal saline in treating temporomandibular myofascial pain.

StrategyJune 29, 2026

Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies

Omega Pharma Ltd is recalling specific batches of Napralief 250mg Gastro-Resistant Tablets due to missing information in the Patient Information Leaflet.

RegulatoryJune 29, 2026

FDA Approval for Oxycodone Hydrochloride Supplement by Sun Pharma

The FDA has approved a supplement for Oxycodone Hydrochloride submitted by Sun Pharma.

RegulatoryJune 29, 2026

FDA Approval Status for Methadone Hydrochloride by ThePharmaNetwork LLC

The FDA has granted approval status (AP) for Methadone Hydrochloride under application ANDA090635 submitted by ThePharmaNetwork LLC.

RegulatoryJune 29, 2026

FDA Approval Status Update for Tramadol Hydrochloride and Acetaminophen

The FDA has provided an approval status update for the ANDA201952 application for Tramadol Hydrochloride and Acetaminophen submitted by Micro Labs Ltd India.

RegulatoryJune 29, 2026

FDA Approves Morphine Sulfate Supplement by Actavis Elizabeth

The FDA has approved a supplement for Morphine Sulfate submitted by Actavis Elizabeth.

RegulatoryJune 29, 2026

FDA Approval Letter for Tramadol Hydrochloride by Sun Pharma

The FDA has issued an approval letter for the ANDA076100 application for Tramadol Hydrochloride submitted by Sun Pharma.

RegulatoryJune 29, 2026

FDA Acceptance of Supplement for Oxycodone Hydrochloride by Epic Pharma

The FDA has accepted a supplemental application for Oxycodone Hydrochloride submitted by Epic Pharma.

RegulatoryJune 29, 2026

FDA Approves Supplemental NDA for NUCYNTA (Tapentadol Hydrochloride)

The FDA has approved a supplemental NDA for NUCYNTA, indicating a new development in its regulatory status.

RegulatoryJune 29, 2026

FDA Approves Supplemental Application for Methadone Hydrochloride Intensol by Hikma

The FDA has approved a supplemental application for Methadone Hydrochloride Intensol submitted by Hikma.

RegulatoryJune 29, 2026

FDA Approves Supplement for Butalbital, Aspirin, Caffeine, and Codeine Phosphate

The FDA has approved a supplemental application for a combination product containing butalbital, aspirin, caffeine, and codeine phosphate.

RegulatoryJune 29, 2026

FDA Approval for Oxycodone Hydrochloride Supplement by Actavis Elizabeth

The FDA has approved a supplement application for Oxycodone Hydrochloride submitted by Actavis Elizabeth.

StrategyJune 29, 2026

Hikma's ANDA090964 for Oxymorphone Hydrochloride Receives AP Status

Hikma's Abbreviated New Drug Application (ANDA090964) for Oxymorphone Hydrochloride has received an Approval Pending (AP) status.

RegulatoryJune 29, 2026

FDA Approval Update for Hydrocodone Bitartrate and Ibuprofen by Amneal Pharmaceuticals

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for a combination of hydrocodone bitartrate and ibuprofen by Amneal Pharmaceuticals.

RegulatoryJune 29, 2026

FDA Approval Status Update for Hydromorphone Hydrochloride by Hikma

The FDA has issued an approval status update for Hikma's ANDA074597 for Hydromorphone Hydrochloride.

RegulatoryJune 29, 2026

FDA Accepts Supplement Application for Oxycodone Hydrochloride by Vistapharm

The FDA has accepted a supplemental application for Oxycodone Hydrochloride submitted by Vistapharm LLC.

StrategyJune 29, 2026

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

The FDA has approved the Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride submitted by Lannett Co Inc.

RegulatoryJune 29, 2026

FDA Acceptance of Supplement for Buprenorphine by Watson Labs Teva

The FDA has accepted a supplemental application for buprenorphine from Watson Labs Teva.

RegulatoryJune 29, 2026

FDA Accepts Supplemental Application for Methadone Hydrochloride by Hikma

The FDA has accepted a supplemental application for Methadone Hydrochloride submitted by Hikma.

RegulatoryJune 29, 2026

FDA Approval of Oxymorphone Hydrochloride Supplement by Actavis Elizabeth

The FDA has approved a supplemental application for Oxymorphone Hydrochloride submitted by Actavis Elizabeth.

RegulatoryJune 28, 2026

FDA Approval Status Update for PERCOCET (ANDA040330)

The FDA has updated the submission status for PERCOCET under ANDA040330 to Approved (AP) with a supplemental application.

RegulatoryJune 28, 2026

FDA Accepts Supplement Application for Teva's Morphine Sulfate

The FDA has accepted a supplemental application for Teva's Morphine Sulfate.

RegulatoryJune 28, 2026

FDA Accepts Supplement for XTAMPZA ER by Collegium Pharma

The FDA has accepted a supplemental application for XTAMPZA ER, an oxycodone-based pain management medication.

RegulatoryJune 28, 2026

FDA Approval Letter for Oxycodone and Acetaminophen Supplement

The FDA has issued an approval letter for the supplement application of Oxycodone and Acetaminophen by Rhodes Pharmaceuticals.

RegulatoryJune 28, 2026

FDA Approval Update for Oxycodone and Acetaminophen by Lannett Co Inc

Lannett Co Inc has received an approval status for their ANDA submission for Oxycodone and Acetaminophen.

RegulatoryJune 28, 2026

FDA Approval for Morphine Sulfate Supplement by Actavis Elizabeth

The FDA has approved a supplement application for Morphine Sulfate submitted by Actavis Elizabeth.

RegulatoryJune 28, 2026

FDA Acceptance of Supplemental Application for Oxycodone Hydrochloride

The FDA has accepted a supplemental application for Oxycodone Hydrochloride submitted by HIBROW HLTHCARE.

CompetitiveJune 28, 2026

Nevro's HF10 Therapy Study for Non-Surgical Refractory Back Pain Underway

Nevro Corp. is conducting a multi-center, randomized study to evaluate the safety and effectiveness of HF10 Therapy for chronic refractory back pain.

RegulatoryJune 28, 2026

FDA Approval for Tramadol Hydrochloride and Acetaminophen Combination

The FDA has approved the ANDA077858 application for a combination of Tramadol Hydrochloride and Acetaminophen.

RegulatoryJune 28, 2026

FDA Approval Letter for Oxycodone Hydrochloride ANDA204979

The FDA has issued an approval letter for Oxycodone Hydrochloride under ANDA204979 submitted by ANI Pharmaceuticals.

RegulatoryJune 28, 2026

FDA Approval Update for Hydrocodone Bitartrate and Acetaminophen by Strides Pharma

The FDA has granted an approval status (AP) for the ANDA040355 application for Hydrocodone Bitartrate and Acetaminophen submitted by Strides Pharma.

RegulatoryJune 28, 2026

FDA Approval for Morphine Sulfate Supplement by Strides Pharma

The FDA has approved a supplemental application for Morphine Sulfate submitted by Strides Pharma.

RegulatoryJune 28, 2026

FDA Acceptance of Supplemental Application for Hydromorphone Hydrochloride by Hikma

The FDA has accepted a supplemental application for Hydromorphone Hydrochloride submitted by Hikma.

RegulatoryJune 28, 2026

FDA Approves Supplemental Application for Methadone Hydrochloride by Vistapharm

The FDA has approved a supplemental application for Methadone Hydrochloride submitted by Vistapharm LLC.

RegulatoryJune 28, 2026

FDA Acceptance of Supplemental NDA for MS CONTIN by KNOA PHARMA

The FDA has accepted a supplemental NDA for MS CONTIN, containing morphine sulfate, submitted by KNOA PHARMA.

RegulatoryJune 28, 2026

FDA Approval Status Update for Hydrocodone Bitartrate by Alvogen

The FDA has issued an approval status update for Alvogen's ANDA206986 for Hydrocodone Bitartrate.

RegulatoryJune 28, 2026

FDA Approval Status for Acetaminophen and Codeine Phosphate (ANDA211610)

The FDA has granted an approval status of 'AP' for ANDA211610, a combination of acetaminophen and codeine phosphate.

RegulatoryJune 28, 2026

FDA Accepts Supplement for NUCYNTA ER by Collegium Pharma

The FDA has accepted a supplemental application for NUCYNTA ER, an opioid pain management medication.

RegulatoryJune 28, 2026

FDA Approval Status Update for Hydromorphone Hydrochloride Supplement

The FDA has granted an approval status of AP for the hydromorphone hydrochloride supplement submitted by Padagis US.

RegulatoryJune 28, 2026

FDA Accepts Supplemental NDA for Oxycodone Hydrochloride by Genus Lifesciences

The FDA has accepted a supplemental NDA for Oxycodone Hydrochloride submitted by Genus Lifesciences.

RegulatoryJune 28, 2026

FDA Acceptance of Supplemental NDA for Oxycodone Hydrochloride by Genus Lifesciences

The FDA has accepted a supplemental NDA for Oxycodone Hydrochloride submitted by Genus Lifesciences.

RegulatoryJune 28, 2026

FDA Approval of Hydrocodone Bitartrate and Acetaminophen Supplement

The FDA has approved a supplemental application for Hydrocodone Bitartrate and Acetaminophen under ANDA205001 by Strides Pharma Intl.

RegulatoryJune 28, 2026

FDA Accepts Supplemental Application for OxyContin by KNOA Pharma

The FDA has accepted a supplemental application for OxyContin submitted by KNOA Pharma.

RegulatoryJune 28, 2026

FDA Approval Update for Tramadol Hydrochloride Supplement by Strides Pharma

Strides Pharma International has received an approval status for the supplemental application of Tramadol Hydrochloride.

RegulatoryJune 28, 2026

FDA Approval for Morphine Sulfate Supplement by Tris Pharma

The FDA has approved a supplemental application for Morphine Sulfate submitted by Tris Pharma.

StrategyJune 28, 2026

FDA Approval Letter for Morphine Sulfate by Upsher Smith Labs

The FDA has issued an approval letter for ANDA210610, indicating that Upsher Smith Labs' morphine sulfate product meets regulatory requirements.

ClinicalJune 28, 2026

Study on rTMS Therapy for Neuropathic Pain in Spinal Cord Injury Patients

The study investigates the efficacy of high-frequency rTMS therapy on neuropathic pain and related outcomes in spinal cord injury patients.

RegulatoryJune 28, 2026

FDA Grants AP Status for OXYCET (ANDA087463) by SPECGX LLC

The FDA has granted Abbreviated Approval (AP) status for OXYCET, a combination of acetaminophen and oxycodone hydrochloride, submitted by SPECGX LLC.

RegulatoryJune 28, 2026

FDA Approval Update for Acetaminophen and Codeine Phosphate by Pharmobedient

The FDA has issued an approval letter for ANDA087006 concerning Acetaminophen and Codeine Phosphate.

RegulatoryJune 28, 2026

FDA Approves Supplemental NDA for OXAYDO by ZYLA

The FDA has approved a supplemental NDA for OXAYDO, an oxycodone hydrochloride product.

StrategyJune 28, 2026

FDA Approval Update for Hydrocodone Bitartrate and Acetaminophen by SPECGX LLC

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Hydrocodone Bitartrate and Acetaminophen submitted by SPECGX LLC.

RegulatoryJune 28, 2026

FDA Approves Supplement for NUCYNTA (Tapentadol Hydrochloride)

The FDA has approved a supplemental application for NUCYNTA, indicating potential new uses or formulations.

RegulatoryJune 28, 2026

FDA Approval for ANEXSIA 7.5/325 by SPECGX LLC

The FDA has granted approval for ANEXSIA 7.5/325, a combination of acetaminophen and hydrocodone bitartrate.

StrategyJune 28, 2026

FDA Approves ANEXSIA 5/325 Submission by SPECGX LLC

The FDA has approved the ANDA submission for ANEXSIA 5/325, containing acetaminophen and hydrocodone bitartrate.

RegulatoryJune 28, 2026

FDA Approves Supplemental Application for Oxycodone and Acetaminophen

The FDA has approved a supplemental application for a combination product containing oxycodone hydrochloride and acetaminophen.

RegulatoryJune 28, 2026

Novitium Pharma's Butalbital Combination Receives FDA Submission Approval

The FDA has approved a supplemental application for a combination product containing Butalbital, Aspirin, Caffeine, and Codeine Phosphate by Novitium Pharma.

RegulatoryJune 28, 2026

FDA Approval Status Update for Acetaminophen and Codeine Phosphate

The FDA has granted an AP status for the ANDA040419 application submitted by SPECGX LLC for Acetaminophen and Codeine Phosphate.

StrategyJune 27, 2026

Hikma's Tapentadol Hydrochloride ANDA205057 Receives AP Status

Hikma's ANDA205057 for Tapentadol Hydrochloride has received Abbreviated Approval (AP) status from the FDA.

RegulatoryJune 27, 2026

FDA Approval Update for Oxycodone Hydrochloride and Acetaminophen

The FDA has issued an approval letter for ANDA203573, a combination of oxycodone hydrochloride and acetaminophen.

RegulatoryJune 27, 2026

FDA Accepts Supplemental Application for Tapentadol Hydrochloride by Novitium Pharma

The FDA has accepted a supplemental application for Tapentadol Hydrochloride submitted by Novitium Pharma.

RegulatoryJune 27, 2026

FDA Approves Supplement for Morphine Sulfate by ANI Pharmaceuticals

ANI Pharmaceuticals received FDA approval for a supplement related to Morphine Sulfate.

RegulatoryJune 27, 2026

FDA Approval for Oxycodone Hydrochloride Supplement by ABHAI LLC

The FDA has approved a supplemental application for Oxycodone Hydrochloride submitted by ABHAI LLC.

StrategyJune 27, 2026

FDA Grants AP Status for Levorphanol Tartrate ANDA213906 by Sun Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Levorphanol Tartrate submitted by Sun Pharma.

StrategyJune 27, 2026

FDA Approval Letter for Tramadol Hydrochloride by Sun Pharma

The FDA has issued an approval letter for the ANDA075964 application for Tramadol Hydrochloride submitted by Sun Pharmaceutical Industries.

ClinicalJune 27, 2026

Study on Ketamine vs Fentanyl for Pain Management in Laparoscopic Cholecystectomy

A randomized double-blind study is comparing intraperitoneal ketamine and fentanyl as adjuvants to bupivacaine for postoperative pain control in laparoscopic cholecystectomy.

RegulatoryJune 27, 2026

Aurobindo Pharma submits supplemental ANDA for Pregabalin

Aurobindo Pharma has submitted a supplemental Abbreviated New Drug Application (ANDA) for Pregabalin.

RegulatoryJune 27, 2026

FDA Acceptance of Supplement for Codeine Sulfate by Hikma

The FDA has accepted a supplemental application for Codeine Sulfate submitted by Hikma.

RegulatoryJune 27, 2026

FDA Approves Supplemental Application for Butrans by KNOA Pharma

The FDA has approved a supplemental application for Butrans, which contains buprenorphine as the active ingredient.

RegulatoryJune 26, 2026

FDA Accepts Supplemental NDA for BELBUCA by BDSI

The FDA has accepted a supplemental NDA for BELBUCA, indicating progress in its regulatory pathway.

RegulatoryJune 26, 2026

FDA Approval Update for FIORICET with Codeine Supplement

The FDA has accepted a supplemental application for FIORICET with Codeine from Actavis Labs.

RegulatoryJune 26, 2026

FDA Accepts Supplemental NDA for Percodan by Endo Operations

The FDA has accepted a supplemental NDA for Percodan, which contains aspirin and oxycodone hydrochloride.

RegulatoryJune 26, 2026

FDA Acceptance of Supplement for Codeine Sulfate by Hikma

The FDA has accepted a supplemental application for Codeine Sulfate from Hikma.

RegulatoryJune 26, 2026

FDA Approves Supplemental Application for Dilaudid by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Dilaudid, containing hydromorphone hydrochloride.

RegulatoryJune 26, 2026

FDA Approves Supplemental NDA for QDOLO (Tramadol Hydrochloride)

The FDA has approved a supplemental NDA for QDOLO, which contains tramadol hydrochloride.

RegulatoryJune 26, 2026

FDA Accepts Supplement for RoxyBond by Protega Pharmaceuticals

The FDA has accepted a supplemental application for RoxyBond, an oxycodone hydrochloride product from Protega Pharmaceuticals.

RegulatoryJune 26, 2026

FDA Acceptance of Supplement Application for NUCYNTA by Collegium Pharma

The FDA has accepted the supplemental application for NUCYNTA (tapentadol hydrochloride) from Collegium Pharmaceutical.

ClinicalJune 26, 2026

Trial Comparing S-ESP vs FICB for Postoperative Pain Relief After Hip Arthroplasty

This trial aims to evaluate the analgesic efficacy of continuous S-ESP block compared to FICB in hip arthroplasty patients.

RegulatoryJune 26, 2026

FDA Accepts Supplemental NDA for Oxycodone Hydrochloride by Vistapharm

The FDA has accepted a supplemental NDA for Oxycodone Hydrochloride submitted by Vistapharm.

RegulatoryJune 26, 2026

FDA Approval Update for Morphine Sulfate by Hikma

The FDA has issued an approval letter for the supplemental application of Morphine Sulfate by Hikma.

RegulatoryJune 26, 2026

FDA Approves Supplement for XTAMPZA ER by Collegium Pharma

The FDA has approved a supplemental application for XTAMPZA ER, an extended-release formulation of oxycodone.

RegulatoryJune 26, 2026

FDA Accepts Supplement for Roxicodone by SPECGX LLC

The FDA has accepted a supplemental application for Roxicodone, indicating ongoing regulatory engagement.

RegulatoryJune 26, 2026

FDA Accepts Supplemental NDA for MS CONTIN by KNOA PHARMA

The FDA has accepted a supplemental NDA for MS CONTIN, an opioid pain management medication containing morphine sulfate.

RegulatoryJune 26, 2026

FDA Acceptance of NUCYNTA ER Supplement Application by Collegium Pharma

The FDA has accepted the supplemental application for NUCYNTA ER, indicating a potential update to its labeling or indications.

RegulatoryJune 26, 2026

FDA Accepts Supplemental NDA for Oxycodone Hydrochloride by Genus Lifesciences

The FDA has accepted a supplemental NDA for Oxycodone Hydrochloride submitted by Genus Lifesciences.

RegulatoryJune 26, 2026

FDA Accepts Supplemental Application for Oxycodone Hydrochloride by Genus Lifesciences

The FDA has accepted a supplemental application for Oxycodone Hydrochloride submitted by Genus Lifesciences.

RegulatoryJune 26, 2026

FDA Accepts Supplemental Application for OxyContin by KNOA Pharma

KNOA Pharma's supplemental application for OxyContin has been accepted by the FDA.

RegulatoryJune 26, 2026

FDA Approves Supplemental Application for OXAYDO by ZYLA

The FDA has approved a supplemental application for OXAYDO, an oxycodone hydrochloride product.

RegulatoryJune 26, 2026

FDA Accepts Supplement Application for NUCYNTA (Tapentadol Hydrochloride)

The FDA has accepted a supplemental application for NUCYNTA, an opioid pain medication.

RegulatoryJune 26, 2026

FDA Accepts Supplement for Demerol (Meperidine Hydrochloride)

The FDA has accepted a supplemental application for Demerol, indicating potential updates to its labeling or usage.

RegulatoryJune 26, 2026

FDA Accepts Supplemental NDA for Conzip by Cipher Pharmaceuticals

The FDA has accepted a supplemental NDA for Conzip, which contains tramadol hydrochloride.

RegulatoryJune 26, 2026

FDA Accepts Supplement Application for SYNALGOS-DC by Sun Pharma

The FDA has accepted a supplemental application for SYNALGOS-DC, a combination analgesic.

RegulatoryJune 26, 2026

FDA Approval of Morphine Sulfate Supplement by Novel Labs

The FDA has approved a supplemental application for Morphine Sulfate submitted by Novel Labs Inc.

RegulatoryJune 26, 2026

FDA Accepts Supplement Application for Oxycodone and Acetaminophen

The FDA has accepted the supplemental application for a combination product of oxycodone hydrochloride and acetaminophen submitted by Mikart.

RegulatoryJune 26, 2026

FDA Approval Update for Tramadol Hydrochloride by Graviti Pharms

The FDA has updated the application status for Tramadol Hydrochloride submitted by Graviti Pharms to AP.

RegulatoryJune 26, 2026

FDA Approval for Hydromorphone Hydrochloride Supplement by Actavis Labs

The FDA has approved a supplemental application for Hydromorphone Hydrochloride submitted by Actavis Labs.

RegulatoryJune 26, 2026

FDA Approves Supplement for Morphine Sulfate by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Morphine Sulfate submitted by Rhodes Pharmaceuticals.

RegulatoryJune 26, 2026

FDA Approval Status Update for Acetaminophen, Caffeine, and Dihydrocodeine Bitartrate

The FDA has provided an approval status update for ANDA204209, a combination product containing acetaminophen, caffeine, and dihydrocodeine bitartrate.

RegulatoryJune 26, 2026

FDA Approves Supplemental Application for CONZIP (Tramadol Hydrochloride)

The FDA has approved a supplemental application for CONZIP, which contains tramadol hydrochloride.

RegulatoryJune 26, 2026

FDA Approval Status for Morphine Sulfate ANDA200812 by Strides Pharma

The FDA has granted approval status (AP) for ANDA200812, a morphine sulfate product from Strides Pharma.

RegulatoryJune 26, 2026

FDA Approves Supplemental NDA for SYNALGOS-DC by Sun Pharma

The FDA has approved a supplemental NDA for SYNALGOS-DC, which contains aspirin, caffeine, and dihydrocodeine bitartrate.

CompetitiveJune 26, 2026

Japet Medical Devices Evaluates JAPET.W+ for Low Back Pain Management

The JAPET.W+ device is being assessed for its effectiveness in managing low back pain through a clinical trial.

StrategyJune 25, 2026

FDA Approves ANDA for Oxymorphone Hydrochloride by Hikma

The FDA has approved the ANDA for Oxymorphone Hydrochloride submitted by Hikma.

RegulatoryJune 25, 2026

FDA Approval Update for Teva's Tramadol Hydrochloride Supplement

Teva's supplemental application for Tramadol Hydrochloride has received an approval status from the FDA.

RegulatoryJune 25, 2026

FDA Approval Update for Tramadol Hydrochloride by SPECGX LLC

The FDA has granted an approval status for the ANDA075983 application concerning Tramadol Hydrochloride.

RegulatoryJune 25, 2026

FDA Accepts Supplement for Codeine Sulfate by Hikma

The FDA has accepted a supplemental application for Codeine Sulfate submitted by Hikma.

RegulatoryJune 25, 2026

FDA Approves Oxycodone Hydrochloride Supplement by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Oxycodone Hydrochloride submitted by Rhodes Pharmaceuticals.

RegulatoryJune 25, 2026

FDA Accepts Supplemental Application for Butrans by KNOA Pharma

The FDA has accepted a supplemental application for Butrans, an opioid pain management product containing buprenorphine.

StrategyJune 25, 2026

FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen

The FDA has issued an approval letter for ANDA207137, a combination of hydrocodone bitartrate and acetaminophen.

RegulatoryJune 25, 2026

FDA Accepts Supplemental Application for Tapentadol Hydrochloride by Epic Pharma

The FDA has accepted a supplemental application for Tapentadol Hydrochloride submitted by Epic Pharma.

RegulatoryJune 25, 2026

FDA Grants AP Status for Mylan's Fentanyl Supplement

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Mylan's fentanyl supplement.

ClinicalJune 25, 2026

Trial Protocol for Liposomal Bupivacaine in Shoulder Arthroscopy Pain Management

This document outlines a randomized controlled trial protocol to evaluate different concentrations of liposomal bupivacaine in ultrasound-guided superior trunk block for postoperative analgesia in shoulder arthroscopy.

ClinicalJune 25, 2026

Study on Medical Cannabis Impact on Opioid Use in Chronic Pain Patients

A randomized controlled trial is evaluating the effect of medical cannabis on opioid dose reduction and pain management in patients with chronic non-cancer pain.

RegulatoryJune 25, 2026

FDA Accepts Supplement Application for BELBUCA (Buprenorphine Hydrochloride)

The FDA has accepted a supplemental application for BELBUCA, an opioid medication.

RegulatoryJune 25, 2026

FDA Approval for Oxycodone Hydrochloride by Novel Labs

The FDA has granted approval for ANDA204021, a supplemental application for Oxycodone Hydrochloride by Novel Labs.

RegulatoryJune 25, 2026

FDA Approval for Amneal's Tramadol Hydrochloride Supplement

The FDA has granted approval for Amneal Pharmaceuticals' supplemental application for Tramadol Hydrochloride.

RegulatoryJune 25, 2026

FDA Accepts Supplement for FIORICET with Codeine

The FDA has accepted a supplemental application for FIORICET with Codeine from Actavis Labs.

RegulatoryJune 25, 2026

FDA Approves Supplement for Morphine Sulfate by Alkem Labs

The FDA has approved a supplemental application for Morphine Sulfate submitted by Alkem Labs.

RegulatoryJune 25, 2026

FDA Approves Oxycodone Hydrochloride Supplement by Strides Pharma

The FDA has approved a supplemental application for Oxycodone Hydrochloride submitted by Strides Pharma.

RegulatoryJune 24, 2026

FDA Approval Update for Oxycodone and Acetaminophen Supplement

The FDA has issued an approval letter for the supplement application of Oxycodone and Acetaminophen submitted by Actavis Elizabeth.

RegulatoryJune 24, 2026

FDA Approval for Methadone Hydrochloride by Sun Pharma

The FDA has approved the supplemental application ANDA208305 for Methadone Hydrochloride submitted by Sun Pharma.

RegulatoryJune 24, 2026

FDA Approval Status Update for Hydromorphone Hydrochloride by Osmotica

The FDA has issued an approval status update for ANDA205629 concerning Hydromorphone Hydrochloride.

RegulatoryJune 24, 2026

FDA Accepts Supplement Application for Roxicodone by SPECGX LLC

The FDA has accepted a supplemental application for Roxicodone, indicating ongoing regulatory engagement.

RegulatoryJune 24, 2026

FDA Approves Supplement for Methadone Hydrochloride by Hikma

The FDA has approved a supplemental application for Methadone Hydrochloride submitted by Hikma.

StrategyJune 24, 2026

FDA Grants Approval for Tramadol Hydrochloride ANDA209404 by Macleods

The FDA has granted approval for ANDA209404, a supplemental application for Tramadol Hydrochloride by Macleods Pharmaceuticals.

RegulatoryJune 24, 2026

FDA Accepts Supplemental Application for Percodan by Endo Operations

The FDA has accepted a supplemental application for Percodan, which contains aspirin and oxycodone hydrochloride.

StrategyJune 24, 2026

Hikma's Roxicet ANDA089351 Receives Abbreviated Approval from FDA

Hikma's Abbreviated New Drug Application (ANDA) for Roxicet has received approval from the FDA.

RegulatoryJune 24, 2026

FDA Accepts Supplemental Application for Oxycodone Hydrochloride

The FDA has accepted a supplemental application for Oxycodone Hydrochloride submitted by Pharm Assoc.

RegulatoryJune 24, 2026

FDA Accepts Supplement for Codeine Sulfate by Hikma

The FDA has accepted a supplemental application for Codeine Sulfate submitted by Hikma.

RegulatoryJune 24, 2026

FDA grants AP status for Fentanyl-75 supplement by Difgen Pharms

The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for a supplement of Fentanyl-75 submitted by Difgen Pharmaceuticals.

RegulatoryJune 24, 2026

FDA Approves Supplemental Application for Methadone Hydrochloride by Vistapharm

The FDA has approved a supplemental application for Methadone Hydrochloride submitted by Vistapharm LLC.

RegulatoryJune 24, 2026

FDA Accepts Supplemental NDA for Dilaudid by Rhodes Pharmaceuticals

The FDA has accepted a supplemental NDA for Dilaudid, an opioid pain medication.

RegulatoryJune 24, 2026

FDA Accepts Supplemental NDA for QDOLO by Rosemont

The FDA has accepted a supplemental NDA for QDOLO, a tramadol hydrochloride formulation, submitted by Rosemont.

RegulatoryJune 24, 2026

FDA Accepts Supplemental Application for Tramadol Hydrochloride by Rubicon Research

The FDA has accepted a supplemental application for Tramadol Hydrochloride submitted by Rubicon Research.

RegulatoryJune 24, 2026

FDA Accepts Supplement Application for RoxyBond (NDA209777)

The FDA has accepted a supplemental application for RoxyBond, an oxycodone hydrochloride formulation.

RegulatoryJune 24, 2026

Aspar Pharmaceuticals recalls Ibuprofen 200mg Tablets due to foil perforations

Aspar Pharmaceuticals Ltd is recalling specific batches of Ibuprofen 200mg Tablets due to foil perforations in some blisters.

RegulatoryJune 24, 2026

ANI Pharmaceuticals submits supplemental application for Oxycodone and Aspirin

ANI Pharmaceuticals has submitted a supplemental application for a combination product containing Oxycodone and Aspirin.

RegulatoryJune 24, 2026

FDA Accepts Supplement Application for Levorphanol Tartrate by Acertis Pharmaceuticals

The FDA has accepted the supplemental application for Levorphanol Tartrate submitted by Acertis Pharmaceuticals.

RegulatoryJune 24, 2026

FDA Approval Letter for Oxycodone and Aspirin Combination

The FDA has issued an approval letter for ANDA040260 concerning a combination of oxycodone and aspirin.

RegulatoryJune 24, 2026

FDA Approval Status Update for Oxycodone Hydrochloride by Pharmobedient

The FDA has provided an approval status update for ANDA206456, a supplemental application for Oxycodone Hydrochloride submitted by Pharmobedient.

StrategyJune 24, 2026

FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen

The FDA has issued an approval letter for ANDA206869, a combination of hydrocodone bitartrate and acetaminophen.

RegulatoryJune 24, 2026

FDA Approval for Tramadol Hydrochloride Supplement by Sun Pharma

The FDA has approved a supplement application for Tramadol Hydrochloride submitted by Sun Pharma.

ClinicalJune 23, 2026

Pilot Study on Pain Medicines Pregabalin and Naproxen in Healthy Adults

A pilot study is testing the analgesic effects of pregabalin and naproxen in healthy adults using controlled pain tests.

CompetitiveJune 23, 2026

Abbott's Study Compares Novel Spinal Cord Stimulation Techniques

A clinical trial is underway to compare a novel spinal cord stimulation lead implantation technique with a standard approach.

RegulatoryJune 23, 2026

Aurobindo Pharma's ANDA218359 for Acetaminophen and Ibuprofen Receives AP Status

Aurobindo Pharma's ANDA218359 for a combination of acetaminophen and ibuprofen has received an Abbreviated Approval (AP) status from the FDA.

ClinicalJune 22, 2026

Novel Diclofenac Potassium Lollipop for Pediatric Postoperative Pain Management

A clinical trial evaluated a weight-adjusted diclofenac potassium lollipop for managing postoperative pain in children after adenotonsillectomy.

ClinicalJune 21, 2026

Study Compares Iovera Cryoneurolysis to Radiofrequency Ablation for Chronic Low Back Pain

A clinical trial is underway to evaluate the efficacy of the iovera° system against radiofrequency ablation for chronic low back pain.

ClinicalJune 20, 2026

Study on Liposomal Bupivacaine for Pain Management in VATS Partial Pneumonectomy

A clinical trial is evaluating the effectiveness of intercostal nerve block with liposomal bupivacaine versus conventional bupivacaine in improving postoperative recovery quality in VATS partial pneumonectomy.

RegulatoryJune 9, 2026

FDA Grants AP Status for Lidocaine Hydrochloride 0.4% in Dextrose 5%

The FDA has granted Abbreviated Approval (AP) status for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.

RegulatoryJune 9, 2026

FDA Approval Status Update for Lidocaine Hydrochloride 0.4% in Dextrose 5%

The FDA has granted an approval status (AP) for ANDA083158, a supplemental application for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.

ClinicalJune 2, 2026

Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction

This clinical trial aims to compare the analgesic efficacy of Serratus Posterior Superior Intercostal Plane Block and Thoracic Paravertebral Block in reducing postoperative opioid consumption after open thoracotomy.

Companies

Assets

Recent signals(207)

Pilot Trial for Simulation-Free Celiac Plexus Pain Ablation Using SBRT Shows Novel Workflow

Medline Issues Correction for Convenience Kits Containing Recalled Lidocaine and Bupivacaine

Evaluating Perineural Catheter for Postoperative Pain in Hindfoot Surgery

FDA Approves Pregabalin Application ANDA219593 by Unichem

FDA Grants Approval for Hydromorphone Hydrochloride ANDA076444

Study on Chronic Pain Patient Preferences for Medication Side Effects

Liposomal Bupivacaine May Enhance Analgesia in Hip Fracture Surgery

Study Compares Systemic Lidocaine to Adductor Canal Block in Knee Surgery

Study on Ropivacaine Plus Triamcinolone for Postoperative Pain Relief After VATS

FDA Approves Supplemental Application for Milnacipran Hydrochloride

FDA Grants AP Status for Milnacipran Hydrochloride by Amneal Pharmaceuticals

Study on Hydromorphone in Multimodal Analgesia for Knee Arthroplasty

FDA Approves First Nonprescription Acetaminophen and Naproxen Combination for Pain Relief

FDA Accepts Pregabalin ANDA211687 Submission from Alvogen

FDA Grants Approval for Methadone Hydrochloride ANDA212093 by Lannett Co Inc

FDA Accepts Supplement Application for Celecoxib by Alembic

FDA Accepts Supplement Application for Ibuprofen and Famotidine by Alkem Labs

Aurobindo Pharma's Diclofenac Sodium ANDA076152 Receives AP Status

FDA Grants Approval for Aurobindo's Etodolac ANDA214872

FDA Accepts Pregabalin Supplement Application ANDA209357 from MSN

FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research

FDA Grants Approval for Novitium's Tramadol Hydrochloride

Trial Comparing Liposomal Bupivacaine and Dexamethasone for Postoperative Pain Control

FDA Approval Letter for Morphine Sulfate by Fresenius Kabi USA

Study on Retrolaminar Block's Impact on Opioid Use in Spine Surgery

Trial Evaluates Superficial Cervical Block to Reduce Opioid Use in Cervical Discectomy

Study on Chronic Post-Surgical Pain Following Video-Assisted Thoracic Surgery Launched

Study on taVNS for Postoperative Pain Management in Thoracoscopic Surgery

FDA Approval Status Update for Buprenorphine Hydrochloride by Rubicon Research

Study on Axillary Block and Analgesic Truncal Blocks for Wrist Surgery

BTL-043 and BTL-899 Devices Show Promise in Alleviating Back Pain

Study Compares R.E.C.K vs Exparel for Pain Management in Robotic Nephrectomy

Trial on Thread-Embedding Acupuncture for Chronic Low Back Pain Initiated

Trial on Bowen Therapy and McGill Exercises for Chronic Low Back Pain Initiated

Study on Shockwave Therapy for Non-Specific Low Back Pain Underway

Study on Erector Spinae Plane Block for Pain Control in Spinal Surgery

Study on Quadro-Iliac Plane Block for Pain Control Post-Lumbar Microdiscectomy

FDA Grants Approval for Dimethyl Sulfoxide ANDA220173

FDA Grants Approval for Morphine Sulfate ANDA213892 by Quagen

FDA Approval for Children's Advil-Flavored Supplement by Haleon

Study on Methocarbamol for Pain Management in Hernia Repair

FDA Approves Pregabalin ANDA219593 by Unichem

Study on Vibratory Anesthesia for Pain Management in Corticosteroid Injections

Study on Pain Neuroscience Education for Chronic Pain Shows Need for Biomechanical Assessment

Study Compares RFA Techniques for Chronic Coccydynia Pain Relief

Trial on Ultrasound-Guided Cervical Plexus Block for VNS Surgery Analgesia

Acupuncture Trial for Heel Pain Syndrome Shows Promise in Pain Relief and Function

FDA Grants AP Status for Hetero Labs' Naproxen ANDA215776

Novitium Pharma's Tramadol Hydrochloride ANDA219647 Receives AP Status

FDA Accepts Supplement for Naproxen by Novitium Pharma

FDA Grants Approval for Naproxen Sodium ANDA212199 by Sciegen Pharmaceuticals

Study on Dexmedetomidine vs Magnesium Sulphate for Thoracotomy Pain Management

Intranasal and IV Oxytocin Study for Pain Relief Shows Potential

Amneal Pharmaceuticals submits ANDA for Milnacipran Hydrochloride

FDA Approval for Children's Advil-Flavored Supplement by Haleon

Strides Pharma's Piroxicam ANDA206136 Receives AP Status from FDA

FDA Grants AP Status for Piroxicam ANDA210347 by Strides Pharma

Study on Botulinum Toxin-A for Temporomandibular Myofascial Pain Outcomes

Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies

FDA Approval for Oxycodone Hydrochloride Supplement by Sun Pharma

FDA Approval Status for Methadone Hydrochloride by ThePharmaNetwork LLC

FDA Approval Status Update for Tramadol Hydrochloride and Acetaminophen

FDA Approves Morphine Sulfate Supplement by Actavis Elizabeth

FDA Approval Letter for Tramadol Hydrochloride by Sun Pharma

FDA Acceptance of Supplement for Oxycodone Hydrochloride by Epic Pharma

FDA Approves Supplemental NDA for NUCYNTA (Tapentadol Hydrochloride)

FDA Approves Supplemental Application for Methadone Hydrochloride Intensol by Hikma

FDA Approves Supplement for Butalbital, Aspirin, Caffeine, and Codeine Phosphate

FDA Approval for Oxycodone Hydrochloride Supplement by Actavis Elizabeth

Hikma's ANDA090964 for Oxymorphone Hydrochloride Receives AP Status

FDA Approval Update for Hydrocodone Bitartrate and Ibuprofen by Amneal Pharmaceuticals

FDA Approval Status Update for Hydromorphone Hydrochloride by Hikma

FDA Accepts Supplement Application for Oxycodone Hydrochloride by Vistapharm

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

FDA Acceptance of Supplement for Buprenorphine by Watson Labs Teva

FDA Accepts Supplemental Application for Methadone Hydrochloride by Hikma

FDA Approval of Oxymorphone Hydrochloride Supplement by Actavis Elizabeth